Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment   crawled time : 16:20    save search
SMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
MDT | $80.38 -1.12% -0.03% 5M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
EW | $88.61 0.98% 0.0% 2M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment for women smart trial platform
FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment
Published: 2024-04-06 (Crawled : 16:20) - biospace.com/
JNJ | News | $148.53 -0.69% 0.11% 67K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
fda treatment for car-t
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
SNY | News | $46.61 -2.27% -2.21% 1.6M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
REGN | News | $906.54 -0.09% -0.08% 280K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
libtayo cell treatment
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
Published: 2023-09-10 (Crawled : 16:20) - crinetics.com
CRNX G | $43.32 -2.04% -2.08% 490K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment study
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
Published: 2023-07-30 (Crawled : 16:20) - globenewswire.com
ANNX | $4.45 0.22% 0.0% 650 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
anx007 treatment trial potential results
Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Published: 2023-06-11 (Crawled : 16:20) - globenewswire.com
NTLA | $21.17 -1.67% -1.75% 710K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
ntla-2002 crispr positive treatment therapeutics study
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
Published: 2023-02-11 (Crawled : 16:20) - globenewswire.com
OCUL | News | $4.645 -7.1% -7.64% 4M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment ongoing ocular trial phase 1
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2022-12-25 (Crawled : 16:20) - globenewswire.com
CHRS | $2.02 -7.34% -7.39% 2.6K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment fda application license review update
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
QURE | $4.56 -4.0% -3.94% 640K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
hemgenix therapy living
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
Published: 2022-12-10 (Crawled : 16:20) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.11% 67K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
FNCTF | News | $11.16 1.13% -20.84% 0 twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
imbruvica treatment glow leukemia response plus results study
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Published: 2022-10-23 (Crawled : 16:20) - globenewswire.com
PHAT | $9.12 0.66% 0.66% 440K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment pharmaceuticals meeting
Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease
Published: 2022-09-11 (Crawled : 16:20) - globenewswire.com
RLAY | $6.35 7.63% 6.94% 1.7M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
rly-4008 treatment disease potential
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Published: 2022-06-25 (Crawled : 16:20) - prnewswire.com
IONS | $42.45 1.46% 1.45% 730K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment hepatitis liver presentation positive international phase 2b chronic hepatitis b
Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-06-05 (Crawled : 16:20) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.11% 67K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
GMAB | News | $28.47 -0.32% -0.32% 420 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
GNMSF | News | $290.34 0.23% 3.83% 0 twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
Published: 2022-06-05 (Crawled : 16:20) - globenewswire.com
HOOK | $0.85 11.11% 9.25% 280K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
hb-200 treatment program asco positive phase 1 phase 2
Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
Published: 2022-06-04 (Crawled : 16:20) - globenewswire.com
BMEA | $10.77 -1.91% -2.04% 140 twitter stocktwits trandingview |
Professional, Scientific, and T...
 | Email alert Add to watchlist
bmf-219 treatment preclinical diabetes potential pre-clinical
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
Published: 2022-05-01 (Crawled : 16:20) - globenewswire.com
KALA | $6.4 -2.53% 4.24% 1.1K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
kpi-012 treatment
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2022-04-27 (Crawled : 16:20) - jaguarhealth.gcs-web.com
JAGX | News | $0.1699 1.13% 1.41% 1.5M twitter stocktwits trandingview |
Health Technology
 | | O: 1.12% H: 6.67% C: 5.8%
treatment drug diarrhea health
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
Published: 2022-04-30 (Crawled : 16:20) - prnewswire.com
MIST | $1.66 -2.35% -1.8% 49K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
node-302 treatment presentation milestone phase 3
KalVista Pharmaceuticals Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief From HAE Attacks in Patients
Published: 2022-02-28 (Crawled : 16:20) - ir.kalvista.com
KALV | News | $10.35 -7.67% -8.41% 480K twitter stocktwits trandingview |
Health Technology
 | | O: -0.62% H: 2.63% C: -0.06%
kvd900 treatment als
Gainers vs Losers
61% 39%

Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M twitter stocktwits trandingview |

BHIL | $0.1793 -4.37% 19.24% 340K twitter stocktwits trandingview |
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K twitter stocktwits trandingview |

CI | $352.28 -0.11% 13.53% 2 twitter stocktwits trandingview |
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K twitter stocktwits trandingview |
n/a
MTH | $154.69 -2.21% 12.68% 450K twitter stocktwits trandingview |
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M twitter stocktwits trandingview |

BMTX 4 | $1.545 0.98% 10.03% 2.5K twitter stocktwits trandingview |
Information
TAL | $12.26 0.57% 9.22% 12M twitter stocktwits trandingview |
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M twitter stocktwits trandingview |
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.